Related News
22Mar
Charles Large to speak at the Schizophrenia International Research Society (SIRS) meeting in Florence 6 – 10th April
0 CommentsStevenage 21st March 2022 – Autifony CEO Charles Large will be speaking in the Pharmaceutical Pipeline session at this year’s... Read More →
20Jul
Charles Large to speak at ‘Fragile X syndrome webinar – in pursuit of a cure’ World Fragile X Day
0 CommentsAutifony CEO Charles Large will be speaking at the webinar ‘Fragile X syndrome – in pursuit of a cure’ World... Read More →
07May
Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting
0 CommentsStevenage 16th April – This weekend Dr Charles Large will present key biomarker efficacy data from a first study of... Read More →
04Mar
Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders
0 CommentsStevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
26Aug
Autifony Therapeutics regains rights to clinical stage Kv3 programme
0 CommentsStevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
Tweets
Autifony CEO Charles Large will be speaking in the Pharmaceutical Pipeline session at this year’s SIRS conference i… https://t.co/L9WSnWTMbV
We are currently recruiting a JNR Medicinal Chemist and a Quality Systems Administrator, for a full job description… https://t.co/6VEPliT1Fg
Autifony CEO Charles Large will be speaking at the a webinar ‘Fragile X syndrome – in pursuit of a cure’ World Frag… https://t.co/DPw8f5LPMN
Comments are closed.